Clinical Trials Logo

Clinical Trial Summary

A Phase 3, Multicenter, open label, study to Evaluate the EFficacy and SaFEty of Leukotac® (inolimomab) in pediatric patients with steroid resistant acute Graft versus Host Disease (SR-aGvHD)


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04289103
Study type Interventional
Source ElsaLys Biotech
Contact
Status Not yet recruiting
Phase Phase 3
Start date October 2021
Completion date June 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05017688 - Prospective Interventional Study Exploring the Microbiota Recolonization in SR-GvHD Patients Receiving MaaT013 N/A
Not yet recruiting NCT06343792 - Safety, PK, PD, Dosing, and Efficacy of RLS-0071for the Treatment of Hospitalized Patients With Steroid-Refractory Acute Graft-versus-Host Disease Phase 2
Recruiting NCT04769895 - MaaT013 as Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients Phase 3
Completed NCT04926194 - Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm Phase 2
Terminated NCT04070781 - Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease Phase 1
Completed NCT05663827 - Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease Phase 3
Terminated NCT01485055 - Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease Phase 2
Completed NCT05052385 - ECP Combination Study
Available NCT04768907 - Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease